



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: HIV-1 NL4-3 Env Expression Vector (pDOLHIVenv)

Catalog Number: 324

Lot Number: 060483

Release Category: A

Provided: 5 µg plasmid DNA (1 µg µl, neomycin resistant).

Cloning Site: *SalI*.

Cloning Vector: pDOL (Korman AJ, et al. *Proc Natl Acad Sci USA* **84**:2150, 1987).

Description: The *SalI*-*XhoI* region of pNL4-3 (Catalog #114) was introduced into the *SalI* site of pDOL. pDOLHIVenv contains the open reading frames for the pNL4-3 env, tat, and rev coding regions. Expression is from the Moloney murine virus LTR.

Plasmid Map

Special Characteristics: The antibiotic β-kanamycin can be substituted for neomycin. Use at a final concentration of 12.5 µg/ml β-kanamycin for liquid culture; use at 25 µg/ml for plates. Keep plates wrapped in foil until use as the antibiotic is light-sensitive. This construct efficiently expresses envelope glycoproteins when transfected into HeLa T4 cells. These transfected cells form syncytia indistinguishable from those formed by HeLa T4 infected with HIV-1. Protein can be detected by immunoprecipitation and immunofluorescence. Digestion with *SalI* or *BamHI* may produce extra bands caused by a site prone to nicking during digestion.

Recommended Storage: -70°C.

Contributor: Dr. Eric O. Freed and Dr. Rex Risser.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References: Freed EO, Myers DJ, Risser R. Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. *J Virol* 63:4670-4675, 1989.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 NL4-3 Env Expression Vector (pDOLHIVenv) from Dr. Eric Freed and Dr. Rex Risser." Also include the reference cited above in any publications.

Last Updated: August 03, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.